Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

ICU Topicstoxicology

ICU · toxicology

Acute Snake Envenomation — Comprehensive (ANZ Context)

Also known as Snakebite envenomation · Snake envenoming · Elapid envenomation · Brown snake bite · Tiger snake bite · Taipan bite · Death adder bite · Venom-induced consumption coagulopathy · VICC · Australian snakebite · Pressure immobilisation bandage · Snake antivenom

Acute snake envenomation in Australia and New Zealand — the world's most venomous snakes belong to the family Elapidae (front-fanged: brown snake [Pseudonaja — 1 cause of snakebite death — procoagulant + presynaptic neurotoxin + rarely thrombotic microangiopathy], tiger snake [Notechis — procoagulant + neurotoxic + myotoxic], taipan [Oxyuranus — most toxic land snake — procoagulant + neurotoxic + myotoxic], death adder [Acanthophis — postsynaptic neurotoxin — curare-like; mechanistically reversible but ASP cohort showed no reversal by antivenom (median resolution 21 h)], black snake [Pseudechis — myotoxic + anticoagulant], rough-scaled snake [Tropidechis — procoagulant + myotoxic], sea snakes [Hydrophiidae — myotoxic + neurotoxic]). Clinical syndromes: (1) PROCOAGULANT → venom-induced consumption coagulopathy [VICC] — prothrombin activators → massive consumption of fibrinogen and factors V, VIII, X → INR 5 + fibrinogen <0.5 + D-dimer massively elevated + PLATELETS NORMAL — but BLEEDING IS RARE despite extreme coagulopathy because the venom clots AND lyses simultaneously (unlike warfarin or DIC — no true anticoagulated state) — give antivenom NOT FFP unless actively bleeding — recovery takes 24-36 h as the liver resynthesises factors (ASP-10). (2) NEUROTOXIC → descending flaccid paralysis: ptosis → ophthalmoplegia → bulbar palsy → limb weakness → respiratory failure — resembles myasthenia gravis (postsynaptic: death adder) or botulism (presynaptic: tiger, brown, taipan) — the pupil reflex and deep tendon reflexes distinguish. (3) MYOTOXIC → muscle pain, tenderness, rising CK (10,000-100,000+), myoglobinuria, AKI — tiger, black, taipan, sea snakes. (4) NEPHROTOXIC → AKI from rhabdomyolysis + direct nephrotoxicity + thrombotic microangiopathy — brown snake. (5) CARDIOVASCULAR COLLAPSE → sudden early collapse (within 1h of bite) — brown snake — thought to be transient hypotension from venom cardiotoxicity or anaphylactoid reaction — high-risk feature. Management: (1) FIRST AID: pressure immobilisation bandage [PIB] — broad bandage over bite site + splint + immobilise the limb — slows LYMPHATIC venom spread (NOT venous — venom moves via lymphatics) — DO NOT remove until antivenom ready in hospital (removal causes venom surge). (2) SNAKE VENOM DETECTION KIT [SVDK] — bite site swab or urine — identifies snake GROUP (brown, tiger, black, death adder, taipan) — guides monovalent antivenom choice — BUT 5% false negative in envenomed patients + 36% false positive in non-envenomed patients — clinical syndromic diagnosis is more reliable. (3) ANTIVENOM: monovalent if snake identified by SVDK or clinical/geographic assessment OR polyvalent if snake unknown — ONE VIAL is sufficient to bind all circulating venom (recent evidence: median dose declined from 4 to 1 vial without harm) — pre-medicate with adrenaline (subcutaneous 0.25 mg) to reduce hypersensitivity reactions (24% reaction rate, 6% severe) — large volumes if polyvalent (dilute in crystalloid, infuse over 30 min). (4) VICC MANAGEMENT: give antivenom — DO NOT give blood products (FFP, cryoprecipitate, platelets) UNLESS actively bleeding — the coagulopathy resolves within 24-36 h as the liver resynthesises factors (ASP-10) — giving FFP 'feeds' the venom prothrombin activator more substrate to consume (paradoxical worsening) and risks transfusion reactions. (5) SUPPORTIVE: mechanical ventilation for neurotoxicity, renal replacement therapy for AKI, treat rhabdomyolysis with fluids. Mortality ~1-2% with antivenom (23 deaths over 10 years in ASP-20; 17 from brown snake).

high18 referencesUpdated 26 July 202631 min readSource-verified · Sept 2026

Checked against its sources on 2 Sept 2026

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • BLEEDING IS RARE in VICC despite INR >10 and unrecordable fibrinogen — the venom simultaneously activates prothrombin (consumes factors) AND activates plasminogen (lyses clot) — there is NO true anticoagulated state — do NOT give FFP/cryoprecipitate/platelets unless the patient is ACTIVELY bleeding — the coagulopathy resolves within 24-36 h irrespective of snake type (ASP-10, ref 18)
  • DO NOT remove the pressure immobilisation bandage until antivenom is ready and IV access established — removal causes a sudden surge of venom into the circulation ('bolus effect') — can precipitate cardiovascular collapse
  • SVDK has a 36% FALSE POSITIVE rate in non-envenomed patients and a 4.9% WRONG-VENOM rate in envenomed patients with a confirmed snake type (the kit detects venom but names the wrong immunotype) — NEVER use SVDK alone to decide on antivenom — diagnose envenoming on CLINICAL and LABORATORY evidence (VICC, neurotoxicity, myotoxicity, collapse)
  • Sudden early collapse (within 1h of brown snake bite) is a HIGH-RISK feature — indicates severe envenoming — cardiovascular collapse may be transient but signals risk of cardiac arrest — treat as an emergency and prepare antivenom immediately
  • Neurotoxicity from presynaptic toxins (tiger, brown, taipan) is NOT reversible by antivenom once established — antivenom prevents further toxin binding but does NOT reverse already-damaged nerve terminals — early antivenom and prolonged ventilation (days) required — contrast with death adder (postsynaptic — mechanistically reversible; anecdotally responds to anticholinesterase, though the ASP cohort found neurotoxicity not reversed by antivenom, median resolution 21 h)
  • Thrombotic microangiopathy (brown snake) — 13% of brown snake VICC cases — presents with severe thrombocytopenia (&lt;20), MAHA, AKI requiring dialysis at 1-3 days post-bite — NOT the same as VICC — platelets ARE low (unlike simple VICC where platelets are normal) — supportive care including dialysis, role of plasma exchange uncertain
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • BLEEDING IS RARE in VICC despite INR >10 and unrecordable fibrinogen — the venom simultaneously activates prothrombin (consumes factors) AND activates plasminogen (lyses clot) — there is NO true anticoagulated state — do NOT give FFP/cryoprecipitate/platelets unless the patient is ACTIVELY bleeding — the coagulopathy resolves within 24-36 h irrespective of snake type (ASP-10, ref 18)
  • DO NOT remove the pressure immobilisation bandage until antivenom is ready and IV access established — removal causes a sudden surge of venom into the circulation ('bolus effect') — can precipitate cardiovascular collapse
  • SVDK has a 36% FALSE POSITIVE rate in non-envenomed patients and a 4.9% WRONG-VENOM rate in envenomed patients with a confirmed snake type (the kit detects venom but names the wrong immunotype) — NEVER use SVDK alone to decide on antivenom — diagnose envenoming on CLINICAL and LABORATORY evidence (VICC, neurotoxicity, myotoxicity, collapse)
  • Sudden early collapse (within 1h of brown snake bite) is a HIGH-RISK feature — indicates severe envenoming — cardiovascular collapse may be transient but signals risk of cardiac arrest — treat as an emergency and prepare antivenom immediately
  • Neurotoxicity from presynaptic toxins (tiger, brown, taipan) is NOT reversible by antivenom once established — antivenom prevents further toxin binding but does NOT reverse already-damaged nerve terminals — early antivenom and prolonged ventilation (days) required — contrast with death adder (postsynaptic — mechanistically reversible; anecdotally responds to anticholinesterase, though the ASP cohort found neurotoxicity not reversed by antivenom, median resolution 21 h)
  • Thrombotic microangiopathy (brown snake) — 13% of brown snake VICC cases — presents with severe thrombocytopenia (&lt;20), MAHA, AKI requiring dialysis at 1-3 days post-bite — NOT the same as VICC — platelets ARE low (unlike simple VICC where platelets are normal) — supportive care including dialysis, role of plasma exchange uncertain
The one-line answer

Australian snake envenomation is an elapid bite whose syndrome maps to the venom — procoagulant (venom-induced consumption coagulopathy, VICC, with an unrecordable INR but normal platelets and rare bleeding), neurotoxic (descending flaccid paralysis), myotoxic (rhabdomyolysis), or early collapse. Keep the pressure immobilisation bandage on until antivenom is ready, give one vial of the monovalent antivenom the syndrome points to, do not give FFP unless the patient is actively bleeding, and ventilate early for presynaptic paralysis.[1]

Meet the patient

A 42-year-old man collapses after a suspected brown snake bite in rural NSW. He arrives alert, BP 95 over 55 after fluids, no active bleeding, INR over 10, fibrinogen unrecordable, D-dimer over 20, platelets 185, CK 220. The pressure immobilisation bandage is still on.[1]

Two questions decide every snakebite: is the patient actually envenomed? (diagnose on the clinical syndrome and labs — never on the SVDK alone), and have I left the bandage on until the antivenom is drawn up? (removal releases a venom bolus). Hold those two and the rest follows.[2]

ICU Fellowship (CICM) Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the ICU Fellowship (CICM) fellowship library.

Sign in to continueSee pricing
References18ShowHide
  1. [1]Isbister GK, Brown SG, Page CB, et al. Snakebite in Australia: a practical approach to diagnosis and treatment Med J Aust, 2013.PMID 24329653
  2. [2]Johnston CI, Ryan NM, Page CB, et al. The Australian Snakebite Project, 2005-2015 (ASP-20) Med J Aust, 2017.PMID 28764620
  3. [3]Isbister GK, Duffull SB, Brown SG; ASP Investigators. Failure of antivenom to improve recovery in Australian snakebite coagulopathy QJM, 2009.PMID 19570990
  4. [4]Cheng AC, Currie BJ. Venomous snakebites worldwide with a focus on the Australia-Pacific region: current management and controversies J Intensive Care Med, 2004.PMID 15358944
  5. [5]Isbister GK, Little M, Cull G, et al. Thrombotic microangiopathy from Australian brown snake (Pseudonaja) envenoming Intern Med J, 2007.PMID 17640187
  6. [6]Isbister GK, Jayamanne S, Mohamed F, et al. A randomized controlled trial of fresh frozen plasma for coagulopathy in Russell's viper (Daboia russelii) envenoming J Thromb Haemost, 2017.PMID 28106331
  7. [7]Maduwage K, Isbister GK. Current treatment for venom-induced consumption coagulopathy resulting from snakebite PLoS Negl Trop Dis, 2014.PMID 25340841
  8. [8]Isbister GK. Snakebite doesn't cause disseminated intravascular coagulation: coagulopathy and thrombotic microangiopathy in snake envenoming Semin Thromb Hemost, 2010.PMID 20614396
  9. [9]Rodrigo C, Gnanathasan A. Adjunct treatment in snakebite envenoming: a systematic review of randomised controlled trials Trans R Soc Trop Med Hyg, 2020.PMID 32780827
  10. [10]de Silva HA, Ryan NM, de Silva HJ. Adverse reactions to snake antivenom, and their prevention and treatment Br J Clin Pharmacol, 2016.PMID 26256124
  11. [11]Ryan NM, Kearney RT, Brown SG, Isbister GK. Incidence of serum sickness after the administration of Australian snake antivenom (ASP-22) Clin Toxicol (Phila), 2016.PMID 26490786
  12. [12]Ryan NM, Downes MA, Isbister GK. Clinical features of serum sickness after Australian snake antivenom Toxicon, 2015.PMID 26525657
  13. [13]Currie B, Fitzmaurice M, Oakley J. Resolution of neurotoxicity with anticholinesterase therapy in death-adder envenomation Med J Aust, 1988.PMID 3367819
  14. [14]Johnston CI, O'Leary MA, Brown SG, et al. Death adder envenoming causes neurotoxicity not reversed by antivenom — Australian Snakebite Project (ASP-16) PLoS Negl Trop Dis, 2012.PMID 23029595
  15. [15]Johnston CI, Isbister GK. Australian snakebite myotoxicity (ASP-23) Clin Toxicol (Phila), 2021.PMID 33156703
  16. [16]Gan M, O'Leary MA, Brown SG, et al. Envenoming by the rough-scaled snake (Tropidechis carinatus): a series of confirmed cases Med J Aust, 2009.PMID 19645653
  17. [17]Silva A, Hodgson WC, Isbister GK. Antivenom for neuromuscular paralysis resulting from snake envenoming Toxins (Basel), 2017.PMID 28422078
  18. [18]Isbister GK, Scorgie FE, O'Leary MA, et al. Factor deficiencies in venom-induced consumption coagulopathy resulting from Australian elapid envenomation: Australian Snakebite Project (ASP-10) J Thromb Haemost, 2010.PMID 20831619

Test yourself

Practise what you just read

  • 8 MCQs
ICU Fellowship (CICM) Pro

$29/ monthor $279 / year

The complete ICU Fellowship (CICM) library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousAcute severe poisonings: decontamination, antidotes, and enhanced eliminationToxicologyNextAcute Tricyclic Antidepressant (TCA) Poisoning — Comprehensive ICU Managementtoxicology